NovoNordisk's high dose Wegovy (semaglutide) has shown improved weightloss while remaining safe and tolerable. In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically ...
with a 20.4% reduction in weight in the REDEFINE 1 study over 68 weeks that fell short of NovoNordisk's hope of a 25% loss. At the least, the new 7.2mg results point to scope for hiking the ...